A capital raise at a steep discount, a reassuring trading update from an NHS-focused surgery provider, a shift from showpiece leathers to funded commercial testing, and fresh clinical data in a rare cancer defined the day's health and biotech news. The common thread was validation, of pipelines, of commercial models, and of balance sheets, even where share prices told a more mixed story.
Sareum raises £3.2m to push psoriasis drug to Phase 2
Sareum Holdings (AIM:SAR) has raised £3.2m before expenses through a subscription for 22.81m new shares priced at 14p, a 49% discount to the 27.5p level at which the stock last closed before trading was suspended on 7 October. The clinical-stage biotech, which develops kinase inhibitors for autoimmune disease and cancer, placed the shares directly with new and existing investors, including two institutional backers introduced by Marex Financial. Shares resumed trading sharply lower, down 37.65% to 16.99p, reflecting the dilution and discount embedded in the deal.
The proceeds are earmarked to carry Sareum's lead asset, SDC-1801, through to a Phase 2-ready position, alongside continued work on its neuroscience programme, with anticipated R&D tax credits topping up general working capital. SDC-1801 is a selective oral TYK2/JAK1 inhibitor aimed initially at psoriasis; the company completed dosing in its Phase 2-enabling toxicology programme in July and is now analysing that data while advancing chemistry, manufacturing and controls work, targeting a full regulatory package by the fourth quarter. Separately, following the conclusion of its collaboration with Receptor.AI, Sareum has synthesised a first batch of blood-brain-barrier-penetrant TYK2/JAK1 compounds and begun early biochemical and ADME testing. The company also intends to launch a retail offer to existing shareholders via the Winterflood Retail Access Platform at the same 14p price.
Sareum flagged that rival brepocitinib reported positive Phase 3 data in dermatomyositis this year and won FDA approval in August as Lisraya, the first approved oral treatment for that condition, a marker of how fast the TYK2/JAK1 field has moved since SDC-1801 entered development.
The financing buys Sareum runway to reach a pivotal data readout, but the terms underline how costly that runway has become: a near-50% discount and heavy dilution are the price of keeping SDC-1801 alive in a field where a direct mechanistic rival has already reached the market. The real test now is whether Sareum's Phase 2-ready package, due by year-end, can differentiate the asset enough to justify the capital already sunk into it.
One Health Group stays on track to meet full-year expectations
One Health Group (AIM:OHGR) reported revenue up 17% to £18.3m for the six months to 30 September, with underlying EBITDA expected to beat the £1.18m posted a year earlier. The AIM-listed provider of NHS-funded elective surgery, which treats patients referred through the NHS Patient Choice pathway, said the first half keeps it on track to meet market expectations of £33.2m to £34m in full-year revenue and £2.6m in underlying EBITDA. Shares rose 5.3% to 308p on the update.
New NHS patient referrals climbed 24% to 11,275, consultations rose 24% to 29,755, and surgical procedures increased 13% to 4,517 against the prior-year period. Annualised revenue per consultant rose 17% to £446,000 even as the consultant pool was deliberately trimmed to 82 from 88 in March, a productivity-driven rationalisation with a further 12 consultants still under review. "Activity was ahead of both the corresponding period last year and the second half of FY26, with growth achieved across all key performance measures," said Adam Binns, chief executive.
The combination of higher referral volumes and a smaller but more productive consultant base suggests One Health is extracting more output per unit of capacity rather than simply growing headcount, a dynamic that should support margins as the group scales toward its full-year targets.
BSF Enterprise starts funded testing with luxury fashion houses
Bsf Enterprise (LSE:BSFA) has moved two luxury fashion house evaluation programmes for its cultivated leather material into funded commercial testing, with the first partner already invoiced for delivered material samples. The London-listed life sciences group, which develops biotechnologies spanning tissue engineering and cellular agriculture, said the move marks a transition for subsidiary Lab-Grown Leather Ltd's cultivated animal leather, branded Elemental Lux™, from early material testing toward proprietary tanning validation and luxury prototype fabrication. Shares rose 14.74% to 1.09p.
Lab-Grown Leather has so far built its commercial identity around one-off showpieces, notably the T-Rex Leather™ flagship handbag Enfin Leve, which carried an auction estimate of €500,000 at Hôtel Drouot in Paris. The latest development describes a different, more repeatable track: structured, partner-funded technical programmes with two unnamed tier-1 global luxury fashion houses, rather than bespoke marketing pieces built for headline value.
Getting a luxury house to pay for testing, rather than simply accepting free samples for evaluation, is a meaningful signal of commercial intent, and shifts Lab-Grown Leather's narrative from speculative showpiece to a nascent, revenue-generating supply relationship, even if the scale remains small for now.
Avacta's faridoxorubicin shows 11.4-month survival in salivary gland cancer patients
Avacta Group (AIM:AVCT) reported that patients with salivary gland cancer treated with its faridoxorubicin (AVA6000) achieved a median progression-free survival of 11.4 months, nearly double the 6 to 6.7 months seen in published historical benchmarks for comparable treatment lines. The clinical-stage life sciences company, which develops targeted peptide drug conjugates for oncology, presented the data from its ongoing Phase 1a/1b trial at the ESMO Congress in Madrid, running 23 to 27 October. Shares were little changed, down 0.47% to 63.0p.
Faridoxorubicin is Avacta's first-generation pre|CISION platform drug, engineered to release a doxorubicin payload directly inside tumours via the fibroblast activation protein, limiting the systemic toxicity that has constrained conventional chemotherapy and antibody-drug conjugates. In the reported efficacy subset of 32 salivary gland cancer patients treated at doses of 310 mg/m2 or above, the durability of response stood out alongside the survival figures. "This is further evidence that the effect of pre|CISION® PDCs can persist even as tumors shrink, an exciting differentiator compared with ADCs and first-generation PDCs, where antigen loss is thought to contribute to the question of durability," said Alan Ho.
Salivary gland cancer is a rare, underserved indication, but the data point to a broader claim Avacta is building its pipeline around: that tumour-activated payload release can sustain efficacy in ways conventional ADCs struggle to match once tumours begin shrinking and target antigen expression falls away.